[Mechanism of thrombocyte aggregation inhibition caused by sulfonylurea compounds. 3. Significance of prostaglandins and cAMP for aggregation inhibiting effect and other effects of sulfonylurea compounds].
D000262:Adenylyl Cyclases / Q000097:blood; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D003994:Bucladesine / Q000494:pharmacology; D000242:Cyclic AMP / Q000494:pharmacology*; D004837:Epinephrine / Q000494:pharmacology; D005934:Glucagon / Q000494:pharmacology; D007093:Imidazoles / Q000494:pharmacology; D007328:Insulin / Q000494:pharmacology; D007545:Isoproterenol / Q000494:pharmacology; D010727:Phosphoric Diester Hydrolases / Q000097:blood; D010973:Platelet Adhesiveness / Q000187:drug effects*; D010974:Platelet Aggregation / Q000187:drug effects*; D011448:Prostaglandin Antagonists / Q000494:pharmacology; D011453:Prostaglandins / Q000494:pharmacology*; D011458:Prostaglandins E / Q000097:blood / Q000494:pharmacology; D011460:Prostaglandins F / Q000494:pharmacology; D051381:Rats; D013453:Sulfonylurea Compounds / Q000494:pharmacology*; D013806:Theophylline / Q000494:pharmacology
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D007093:Imidazoles; D007328:Insulin; D011448:Prostaglandin Antagonists; D011453:Prostaglandins; D011458:Prostaglandins E; D011460:Prostaglandins F; D013453:Sulfonylurea Compounds; D003994:Bucladesine; D005934:Glucagon; D013806:Theophylline; D000242:Cyclic AMP; D010727:Phosphoric Diester Hydrolases; D000262:Adenylyl Cyclases; D007545:Isoproterenol; D004837:Epinephrine
Experimentelle Untersuchungen zum Mechanismus der durch Sulfonylharnstoffe verursachten Hemmung der Thrombozytenaggregation